AC Immune (NASDAQ: ACIU) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare AC Immune to related businesses based on the strength of its dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.
This is a breakdown of current recommendations for AC Immune and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AC Immune Competitors||556||2480||6723||133||2.65|
Earnings and Valuation
This table compares AC Immune and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AC Immune||$23.55 million||-$7.20 million||N/A|
|AC Immune Competitors||$217.40 million||-$39.57 million||-55.48|
AC Immune’s competitors have higher revenue, but lower earnings than AC Immune.
Insider & Institutional Ownership
17.1% of AC Immune shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility & Risk
AC Immune has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Comparatively, AC Immune’s competitors have a beta of 1.47, meaning that their average stock price is 47% more volatile than the S&P 500.
This table compares AC Immune and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AC Immune Competitors||-4,690.20%||-479.45%||-42.75%|
AC Immune beats its competitors on 8 of the 12 factors compared.
AC Immune Company Profile
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.